It looks like around 3.25 mil cash available with a 13.5 million market cap.If they can reach and maintain a 15 mil market cap again they will be positioned to apply for NYSE listing. Rumor has it that this will happen this year. Also the low cash on hand is not a reason for alarm.The company has stated that their strategy is to monetize before going deep into expensive phase 3 trials thru sale or merger. This is unique in comparison to my other psych holdings which I've been in since 2020 and still probably 5 years away from reaching fda approval on a promising drug for the big payoff. There low outstanding shares are also encouraging for a good return on investment. Bottom line imo is that for the price it would be tough to lose investment on medium term holding. Pharmaceutical/biomed companies like this are much more likely to be bought or merge as opposed to going out of business. I'm in big for 1-2 years. It will be interesting.
News 
Market Data 
Discover 
